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Abstract Needle and Syringe Exchange Programs (NSP) prevent infectious diseases in
community and prisons. Less than 1 % of prisons worldwide have NSP. One barrier is
organizational concern for needle stick injuries from used syringes. Given these concerns,
we introduced retractable syringes into our prison NSP and evaluated 1) injection drug users’
experiences with retractable syringes and 2) beliefs and knowledge about NSP among prison
officers (PO) and healthcare staff (HS). In 2010, we replaced usual syringes with retractable
needle devices in the prison of Champ-Dollon, Geneva, Switzerland. We examined demo-
graphics, clinical profiles and NSP use among NSP participants, and asked about ease and
safety of retractable syringes use in interviews. We distributed questionnaires to PO and HS, to
assess knowledge and general opinions on NSP. The majority of participants expressed that
retractable syringes were acceptable alternatives, but needed improvements. Of the question-
naires, 90.3 % of PO and 9.6 % of HS were still concerned about misuse of soiled syringes as
weapons. Improving the quality and ease of use of use may increase the acceptance of
retractable syringes. Continuing to address PO and HS safety concerns is an important step
towards more disseminated NSP implementation and useful innovation.
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HBV Hepatitis B virus
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IDU Injection Drug User(s)
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Injection Drug Use—a Commonality Among Prisoners
Injection drug use in prison carries a high risk for infection with blood-borne viruses (BBV)
that contribute to a high degree of morbidity and mortality–human immunodeficiency virus
(HIV), hepatitis B (HBV) and hepatitis C virus (HCV) (Stark et al. 2006). Additionally,
transmission of BBV in prison is a growing crisis worldwide due to the increased imprison-
ment of individuals who are users or who deal drugs, and the overcrowding of prisons in many
settings. Time in prison is common for injection drug users (IDU) given the illegality of drug
use and criminal behavior due to the high price of drugs on the black market (Office Fédéral de
la Statistique 2010; Jürgens et al. 2009): 56–90 % of drug users have been imprisoned at least
once in their lifetime, and drug use before imprisonment has been reported by up to 73 % of all
prisoners (European Monitoring Centre for Drugs and Drug Addiction 2011a, b; Jürgens et al.
2011). Studies in the US have shown that 80 % of detainees had a history of drug use, with
20 % of them identifying as IDU, and 12 % reporting current injection use at the time of their
arrest (CDC and Centers for Disease Control and Prevention 2001; Mumola, 1999; Thiede
et al. 2001).
Risks of Intravenous Drug Use in Prison
Despite efforts to eradicate drug use or trafficking in prison, prisoners manage to
attain access to illegal drugs; up to a third of prisoners engage in first-time use during
incarceration (European Monitoring Centre for Drugs and Drug Addiction 2011a, b;
Todts et al. 2007; Jürgens, 2007). The risk of BBV in prisons is amplified due to the
large number of IDU who continually inject in this unique setting, where, the
population is constantly changing and composed of individuals from different
places- resulting in a higher number of injecting partners from diverse communities
(Dolan et al. 2003).
Prison stays are also associated with behaviors that compound infectious risks linked to
drug use. Prison drug users often take too little time to bleach their equipment correctly, and
consume drugs quickly for fear of being caught. As well, the scarcity of sterile injection
material among prisoners promotes sharing (European Monitoring Centre for Drugs and Drug
Addiction 2004; Dolan, 2000; Lines et al. 2006). Scarce equipment compels prisoners infected
with HIVand HCV to keep their condition secret, yet continue sharing tainted material (Bruce
and Schleifer 2008). In the absence of harm reduction measures, incarceration is an indepen-
dent risk factor for hepatitis C among drug users (Global Comission on Drug Policy 2013).
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Use of tainted injecting equipment in prison has also been found to be the most significant risk
factor for HIV infection (Jürgens et al. 2009; Larney, 2010).
Needle and Syringe Programs (NSP) as an Effective Harm Reduction Measure in Prison
One important intervention has been the provision of clean injecting equipment through needle
and syringe programs (NSP) to reduce unsafe injecting. NSP started out in an Amsterdam
community setting in 1981 due to a HBV outbreak among injection drug users (Wodak and
Cooney 2006), and programs have been implemented in more than 80 countries since then
(Harm Reduction International 2010). Many studies have demonstrated the efficiency of NSP
to reduce transmission of blood-borne diseases (especially HIV), highlighting its cost-
effectiveness and its ability to streamline direct access to support services for drug users
(Harm Reduction International 2010; World Health Organization 2004; Degenhardt et al.
2010).
The evidence available from the few existing prison NSP suggests that their
benefits are similar to community programs, and there is no valid suggestion to date,
that these programs are unsafe or increase drug use (Wodak and Cooney 2006). NSP
started in Swiss prisons in 1992, and the 1994 pilot Hindelbank program showed
near-elimination of shared injection equipment after 1 year, and decreased new BBV
infections over time (Dolan et al. 2003). NSP have also been shown to be effective in
reducing HIV infections in prison among 10 systematic HIV evaluations (Jürgens
et al. 2009, 2011). Evaluations in prison show that they do not lead to increased
injection drug use (Stark et al. 2006); nor are they used as weapons against prison
officers or other inmates (Dolan, 2000), or cause health issues for prison workers
(Mogg and Levy 2009). Finally, prison NSP encourages the transition of IDU to drug
rehabilitation and addiction programs (Jürgens et al. 2009, 2011).
WHO recommends that “prison authorities in countries experiencing or threatened by an
epidemic of HIV infections among IDU should introduce NSP urgently and expand
implementation to scale as soon as possible” (Harm Reduction International 2010; Mogg
and Levy 2009). Still, only 60 prisons in 10 countries have implemented such programs.
Different political and perceived risk barriers related to these programs stand in the way of
sustainability and continued implementation. One example is Germany, where despite the
success of seven prison programs by 2000, the majority closed due to decisions by the
newly elected conservative state governments despite protest from prison staff (Jürgens
et al. 2011). Even in Switzerland, where harm reduction is part of official drug policy, only
13 of the 115 prisons have instituted NSP.
Fears and Barriers Surrounding NSP—a Motivation for Retractable Devices
Because there is public worry regarding inappropriate syringe disposal and the perceived risk
to the wider community due to needle stick injury, replacing current injecting equipment
distributed by NSP with retractable syringes/needles, has been a tried method in community
settings (although difficult to assess the level of impact, given the low risk of BBV infection
following needle-stick injury in the community) (Wodak and Cooney 2006; Kermode et al.
2003). A retractable device is made up of a needle and syringe where the needle retracts inside
the barrel when the plunger is automatically/manually completely pushed down. Originally
developed to decrease the number of needle-stick injuries in hospitals, one university hospital
study did show decreased needle-stick injuries by 49 % (Whitby et al. 2008). In this study, we
aimed to assess acceptability and safety of retractable syringes with filters for NSP among
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IDU, and perceptions regarding NSP between prison officers (PO) and healthcare staff (HS)
working in the prison of Champ-Dollon in Geneva, Switzerland.
We know that drug user acceptance is critical for the successful implementation of
any new injection equipment (Des Jarlais, 1998), and also that views of prison stake-
holders must be taken into account to fully integrate NSP (Mogg and Levy 2009). Our
study is unique for two reasons: this is the first time that a trial of retractable devices in
a prison NSP was conducted with injection drug users as active collaborators, and as
well, we described the perceptions of prisoner officers and healthcare staff regarding
general NSP.
Methods
Setting
This observational study took place in Switzerland’s largest pre-trial prison (Champ-Dollon,
Geneva), with a capacity for 376 detainees. The prison is overcrowded and had a mean
occupation rate of 162 % in 2010 (Wolff, 2010). One-third has consumed heroin or cocaine
at least once in their life. Forty percent of detainees have consumed illegal drugs within
30 days of detention. Hepatitis C is diagnosed in 5.6 % of the inmates, chronic hepatitis B in
1 % and HIV in 1 % (Wolff et al. 2011).
Prison health care is based on the Swiss drug policy, which relies on the four pillars model
(prevention, treatment, harm reduction and repression) (Federal authority of the Swiss
Conferederation, 2011). The harm reduction arm consists of a targeted approach towards drug
users, and relies on proven measures like NSP, distribution of condoms with safe sex
recommendations, opioid substitution treatment programs (OST) and heroin prescription
programs (Addiction Suisse, 2013). NSP started in Champ-Dollon’s prison in 1996, but state
authorities gave formal authorization in 2000.
Program Intervention
From April to November 2010, we replaced conventional 1-ml-insulin syringes contained in
the “Flash Box”, used in community NSP and traditional prison NSP, with retractable syringes
developed by Unilife. These retractable syringes contained a mechanism allowing for manual
control of needle retraction by the user. In community needle exchange facilities in
Switzerland, syringes with built-in filters are usually provided, and so Unilife developed (at
our request) an adaptor for those filters.
Each IV drug user entering the prison was informed during a systematic screening
process of the existence of the needle and syringe exchange program. Patients were
notified that they could request injection equipment from the healthcare staff (HS). If
material was requested, they were invited to the prison medical unit for a confidential
consultation aiming to explain the NSP procedure, and also to discuss practical issues
related to drug use. The functioning of all equipment was explained at this visit and
prevention and harm risk reduction messages were provided. Participating inmates gave
written, informed consent and agreed to provide feedback about their experiences,
particularly the introduction of the retractable syringes, as well as to include their clinical
and demographic information. They were informed that a study nurse would contact him/
her to conduct a short demographic interview (first part) and evaluation about the
experience (second part).
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IDU Evaluation
A short first interview was conducted with the study nurse to collect nationality, verify
identification number and age, type of incarceration, duration of injection drug use, primary
language spoken, and confirm consent.
Interview questions on client perception and satisfaction for the patient evaluation of the
NSP were created in collaboration with addiction specialists and prison health care workers
who have worked in NSP and participated in NSP improvement measures. The study nurse
called patients back for questions after 2 to 3 weeks of trial use. Eleven statements focusing on
the introduction of retractable syringes and its usability/acceptability were addressed in the
interview with answer options being “strongly agree,” “agree,” “neither agree nor disagree,”
“disagree,” and “strongly disagree.” Patients were also allowed to qualitatively elaborate on
their responses. For these analyses, patients who “strongly agreed” or “agreed” were counted
as agreeing to the statement.
Prison Officer (PO) and Healthcare Staff (HS) Questionnaire
For a more general overview of perceptions about NSP from the prison and medical staff
perspective, we distributed a written, self-administered questionnaire to all PO and HS. Again,
interview questions were developed in collaboration with addiction specialists and prison health
care workers who have worked in NSP and participated in NSP improvement measures. On one
study day, we distributed 100 anonymous questionnaires to all prison and medical workers with
prisoner contact. The questionnaire titled “Infectious Disease Questionnaire” included 14
statements focusing on knowledge and perceptions about drug use, infectious diseases trans-
mission, harm reduction and NSP. Answer options were “not at all”, “no”, “yes”, and “abso-
lutely.” Respondents were also allowed to qualitatively elaborate on their responses. For these
analyses, “yes” and “absolutely” responses were counted together versus “not at all” and “no.”
Analysis
Descriptive analyses concerning demographics, clinical profiles and interviews responses were
carried out for the IDU. We describe PO and HS agreement to questionnaire statements.
The study received approval by the ethical commission for research of the Geneva
University Hospitals (CER 09–016).
Results
Characteristics of NSP Participants (Table 1)
The average age of the 28 NSP participants was 32 years, with 27 of them being male. Most of
the participants were from Eastern Europe (75 %). About 4 % of the participants were HIV-
positive and 32.1 % had never been screened. We found one case of abscess at the injecting
point during the study period.
Equipment Distribution
From April to November 2010, 284 retractable devices were distributed to 28 of 2,050 inmates
in the Champ-Dollon prison. Overall, 201 syringes were returned for exchange, yielding a
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return rate of 70 %. Health care workers observed that the filters, adapters and ascorbic acid
distributed with the syringes were frequently returned unused (safety filters were not being
used). Disassembled syringes were also found in the returned syringes, prompting the suppo-
sition that the engineered spring of the mechanism was used for other purposes.
IDU Experiences (Table 2)
Of the 28 who inquired about NSP, 26 inmates agreed to continue in the study and
had the first interview encounter. However, 13 inmates were released before having
the second interview (which evaluated the retractable syringes in the NSP). Of the 13
remaining participants, only ten had actually used the syringes and continued with the
second interview (three were released before receiving their first syringe). Of note,
there were no significant differences in terms of demographics and clinical profiles
between the 28 initial participants and the 10 participants who completed the study.
Of the ten participants who completed the study, six (60 %) agreed that retractable
syringes are a useful tool, particularly adapted for prison settings; nine (90 %) agreed
on the fact that using retractable NSP devices helps to protect others from potential
infectious disease. They noted that retractable syringes were not more difficult to use,
but that preparation and injection process took more time (60 %). All agreed that the
mechanism worked well, with some differing opinions concerning its efficiency as
Table 1 Characteristics of initial NSP participants (n=28)
Demographics Mean (SD), range or N (%)
Age (years) 31.2 (4.8), 21–42
Male 27 (96.4)
Nationality N (%)
Algeria 2 (7.1)
Armenia 1 (3.6)
Bosnia-Herzegovina 1 (3.6)
Chile 1 (3.6)
France 3 (10.7)
Georgia 13 (46.4)
Lithuania 1 (3.6)
Romania 2 (7.1)
Russia 3 (10.7)
Ukraine 1 (3.6)
Detentions and injection use Mean (SD), range
Time (weeks) of detention 12.3 (24.6), 0–115
Number of incarcerations 4.6 (8.4), 1–45
Length (days) of overall incarceration 125.5 (170.4), 5–690
Time (months) of injection use 92.9 (88.7), 0–324
Infection history N (%)
HIV- positive, negative, unknown 1 (3.6), 18 (64.3), 9 (32.1)
HBV- positive, remission, negative, unknown 2 (7.1), 5 (17.9), 12 (42.9), 9 (32.1)
HCV- positive, remission, negative, unknown 17 (60.7), 1 (3.6), 3 (10.7), 7 (25)
Injection site abscess- yes, no, unknown 1 (3.6), 24 (85.7), 3 (10.7)
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demonstrated by the mixed responses concerning need for specific training, ability to
use syringe with either hand, safety mechanism and view of the injection substance
(Table 2).
In qualitative follow-up, one (10 %) participant complained that retractable syringes
were heavier than normal. Three users (30 %) complained also about the needle sharp-
ness, describing that injections were more painful or more difficult, comparing the
feeling to “injections with used needles.” They noted that if the injection failed, they
actually lost the product (drug), because they needed to break the syringe to recover it
(no “second chances”). A participant pointed out that they could reuse syringes if they
did not depress the plunger completely. IDU expressed the difficulty in adjusting the
filter and adaptor to the syringe, making the preparation of the injection longer. However,
40 % of the users agreed that they would use retractable NSP syringes outside prison
(10 % “strongly agreed”, 30 % “agreed”, 20 % “neither agreed nor disagreed”, 30 %
“disagreed” and 10 % didn’t answer, Table 2).
Description of PO and HS Knowledge and Perceptions (Table 3)
We interviewed 72 PO and 21 HS. Both groups thought that infection risk was an important
issue for inmates, HS (95.4 %), PO (88.4 %); they agreed on reduction of overcrowding as a
method to address risk, HS (66.7 %), PO (54.6 %); PO were aware of the use of drugs in
prison- 79 % agreed that smoked drugs are used in the prison and 61 % of them agreed with
the statement that IV drugs were being used. HS perceptions were slightly higher: 90 %
thought that smoked drugs were currently used, and 80 % had this opinion about injection
drugs. Overall, 87.5 % of the PO responded positively that regular training on this subject was
important and needed, similar to HS (91 %).
Table 2 IDU responses about retractable syringes
Questionnaire Statement Strongly
Agree
Agree Neither
Agree/
Disagree
Disagree Strongly
Disagree
N (%) N
(%)
N (%) N (%) N (%)
I think that the retractable syringes are useful 4 (40) 2 (20) 1 (10) 2 (20) 1 (10)
The retractable syringes is easy to use 1 (10) 2 (20) 4 (40) 1 (10) 2 (20)
I do not need a specific training to use the
retractable syringe
2 (20) 3 (30) 2 (20) 2 (20) 1 (10)
The retractable syringe can be used with both hands 2 (20) 3 (30) 1 (10) 0 (0) 2 (20)
The syringe safety mechanism works in a satisfactory manner 1 (10) 3 (30) 3 (30) 2 (20) 0 (0)
It is easy to know when the safety mechanism is activated 1 (10) 6 (60) 3 (30) 0 (0) 0 (0)
The retractable syringe permits a good view of the injected
substance
1 (10) 4 (40) 2 (20) 2 (20) 0 (0)
An injection with the retractable syringe takes more time than
the traditional/standard version
3 (30) 3 (30) 2 (20) 1 (10) 0 (0)
Using retractable syringes protects the person who shares my
living quarters
7 (70) 2 (20) 0 (0) 0 (0) 0 (0)
The number of syringes dispensed by the nurse is adequate 4 (40) 3 (30) 2 (20) 1 (10) 0 (0)
After I am released, I would like to continue using these type
of syringes
1 (10) 3 (30) 2 (20) 3 (30) 0 (0)
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Half of the PO stated that they were well trained and had information about the risks of
transmission of infectious diseases, compared to 95 % of HS. The majority of PO were
concerned by the risk of acquiring an infectious disease in prison posed for themselves
(90.2 % agreed this was a risk), while the HS considered themselves less exposed (47.7 %).
Concerning the efficacy of harm reduction measures, 74 % of PO agreed that NSP are
efficient in the community while 100 % of HS had this opinion. For prison NSP, 71 % of PO
agreed with their utility while 100 % of HS supported prison NSP. The differences between PO
and HS were similar in reference to community and prison OSTwith 100 % HS agreeing with
OST measures.
Despite the fact that no aggression with a syringe has been reported in this setting (Rieder,
2009; Services and of Canada, 2003), 90 % of PO agreed with the statement that syringes
could be misused as weapons; only 10 % of HS expressed this perception. Seventy-seven
percent of PO agreed that providing sterile syringes might increase drug use in prison, whereas
only 5 % of HS agreed with this statement.
Discussion
In our study, NSP with retractable syringes was perceived as an acceptable alternative for
incarcerated injection drug users, although there were some technical caveats among users.
They complained about difficulties due to the weight of the syringe and needle quality, as well
as the difficulty to install and use the syringe filter. Of the 98 questionnaires distributed to PO
Table 3 Comparing responses about harm reduction programs, between prison officers and prison healthcare
staff (responded “yes” or “absolutely”)
Questionnaire statement Prison
officers
Health
staff
N (%) N (%)
Prison staff are well taught and informed about the risk for infectious diseases (ID) 36 (50) 20 (95)
ID risk is an important issue for prison staff 65 (90.2) 10 (47.7)
ID risk is an important issue for inmates 61 (88.4) 20 (95.4)
The most efficient method to reduce ID risk is to reduce overcrowding at this prison 37 (54.6) 14 (66.7)
Illegal drug use by sniffing or smoking is common among inmates at this prison 53 (79.1) 18 (90)
Illegal drug use by IV is common among inmates at this prison 39 (61) 15 (78.9)
Offering sterile injection material to IDU in the community setting is an effective way to
reduce the transmission of viral hepatitis
51 (73.9) 21 (100)
Offering sterile injection material to IDU while in this prison is an effective way to
reduce the transmission of viral hepatitis
49 (71) 21 (100)
Offering OST in the community setting to individuals who are opioid dependent is an
effective way to reduce the transmission of viral hepatitis
48 (73.8) 21 (100)
Offering OST in this prison setting to individuals who are opioid dependent is an
effective way to reduce the transmission of viral hepatitis
47 (70.2) 21 (100)
I feel that IDU could use a syringe as a weapon, against me 65 (90.3) 2 (9.6)
I believe that offering sterile injection to IDU, encourages and promotes more drug use 54 (76.1) 1 (4.8)
I think that, being in this line of work, I have a higher chance of being infected with
tuberculosis, than with HIVor hepatitis
37 (52.8) 13 (61.9)
Regular education and training on different aspects of ID is important for all the staff
working at this prison
63 (87.5) 19 (90.5)
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and HS, 70 % of PO and 100 % of HS thought that harm reduction policies like NSP were an
effective means to reduce the risk of BBV infections. However, 90.3 % of PO were still
concerned about the use of soiled syringes as weapons.
IDU Experiences
Preliminary evidence about retractable devices in NSP is concerning, as many user issues have
yet to be acknowledged in studies (Fry, 2006). There is a need to engage in consultation and
partnership in any research that involves IDU, and test empirically the impact of introducing
new devices on a range of factors. In this case, these factors include syringe disposal practices,
community perceptions (prison worker and staff perceptions in this prison case setting), the
risk of needle stick injury, and syringe sharing practices among injection drug users. Ensuring
acceptability by injection drug users is essential in maintaining NSP effectiveness (Kermode
et al. 2003).
In our case, we found that there is much room for improvement. The fact that many
syringes were used without filters is a problem in terms of harm reduction, considering the
utility of the filter in avoiding injection of insoluble particles, which can lead to embolism or
talcosis. Another possible reason explaining why filters were not used, is user fear of losing
drug between the different membranes. This fear was reinforced in discussions of the safety
mechanism itself, which they stated did not allow for “second chances” if the user missed the
injection. IDU also stated that the syringe felt heavier and that the new needle made the
injection more painful. Thus improvements to be made in the material include: better quality
needles, lighter syringes, and adapted filters, which are easier and quicker to use.
Encouragingly, 90 % of the IDU strongly agreed that retractable devices could reduce the
risk of transmission of infectious disease. IDU considered retractable syringes as an acceptable
alternative, despite equipment imperfections, particularly because they thought “using retract-
able NSP devices helps to protect others from potential infectious disease.”
However, during the trial period, we noted a reduction in the return of used syringes
compared to 2009: a return rate of 70 %, compared to 83.2 % in the pre-study NSP (Wolff,
2010). Under the criteria established by WHO in collaboration with UNODC and UNAIDS,
about 200 syringes per injection user per year reflects a high level of availability (Arnaud et al.
2011)- this translates to about 100 syringes per user for the 6–7 month study period observed
here (as an ideal number). Given the 28 IDU enrolled into the NSP, the returned number of
syringes is sub-par. Retractable devices were also returned dismantled, which poses the
question as to what other functions they carried.
Staff NSP Perceptions
Previous reports have proposed that engaging prison staff more often in NSP development will
address the opposition of correctional authorities (Mogg and Levy 2009). By understanding the
views and the underlying motivations of those who oppose NSP or NSP innovations, it will be
far easier to influence perceptions. As stated previously, “involving all stakeholders, especially
prison authorities, creates a sense of ownership of whatever solution is devised and therefore
increases the chances of the intervention succeeding” (Mogg and Levy 2009). Since the
inception of NSP at Champ-Dollon, there has never been a case of a syringe used as a weapon.
But despite more than 15 years of experience without incident, NSP is still perceived as
potentially dangerous by the PO. This perspective was an important finding of this study.
Although our limited cohort is too small to look for differences between PO and HS
perceptions, we describe a general view regarding the use of syringes as weapons, the risk of
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being infected in the prison, the level of formation concerning infectious diseases transmission,
the efficiency of harm reduction measures (particularly NSP), and whether distribution of
syringes increases drug consumption in prison. Overall, evaluation of NSP was positive.
Given these findings, the dispensation of preventive messages and trainings at regular intervals
concerning infectious diseases (while highlighting PO and HS perceptions and addressing the
gaps in knowledge base) will be a way to improve the understanding of harm reduction programs
and their need to be implemented in prisons (true cost and benefit ratio).
Limitations
Firstly this is an observational, descriptive study with a low number of participants, which may
limit generalization to other settings. Nevertheless, we believe that this unique study sheds
some insight into important issues from the prisoner and staff perspective. A possible
explanation for the low NSP user turnout for the study is that there may not have been enough
information disseminated about the program, although efforts were made on many front to
ensure prisoner awareness. As well, perhaps the interval between syringe requests and
distribution (even if short, in general only a few hours) or the need for face-to-face distribution
with a medical provider (stigma) was as an obstacle for the drug users. The subsequent dropout
was primarily due to early liberation of participants. The pre-trial detention setting makes it
difficult to plan interviews, due to the incertitude of prisoners release status.
Take-home Messages
In general, very little literature about prison NSP incorporates the acceptability, knowledge and
attitudes of users and prison stakeholders (Mogg and Levy 2009; Ferrer-Castro et al. 2012). The
introduction of retractable needles into NSP will result in a decrease in syringe sharing, only if
accepted by injection drug users as an equally good alternative (Kermode et al. 2003). Here, the
trial group of IDU accepted retractable syringes. Nevertheless improvements are necessary to
increase the use of those syringes, specifically in the filtering and injecting process. Improving
retractable devices in their quality and ease of use can increase their acceptance.
For PO working in a prison with a well-functioning NSP, a perceived fear that syringes are
used as weapons and/or encourage drug use remains, despite general acceptance. Whether
retractable syringes can also help ease security concerns of this prison administration remains
to be seen in further trials. The introduction and innovation of NSP in prisons, as in the
community, is a step forward in a worldwide movement of addressing health disparities among
prisoners, especially as the prison population globally expands (Jürgens et al. 2009).
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